Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight loss and ...

Zepbound is the preferred weight loss medicine vs. Wegovy and has consistently beaten the latter in U.S. weekly prescriptions ...

US pharma major Eli Lilly (NYSE: LLY) yesterday announced executive leadership transitions that will further enhance the ...

Semaglutide and tirzepatide aid weight loss by mimicking gut hormones Ozempic, Wegovy, Mounjaro and Zepbound treat diabetes, support weight loss The weight loss drugs differ in FDA-approved uses ...

Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to ...

Ozempic is what's known as a GLP-1, a drug class that's prescribed to manage Type 2 diabetes and is effective for weight loss.

Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

Columbia University and NewYork-Presbyterian Hospital agreed to pay $750 million to settle hundreds of sexual abuse claims ...

Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo Nordisk, after negotiating a price cut with the company, along with Novo ...

Market volatility and near-term uncertainty can be challenging to deal with these days -- or at any time. Let's consider four ...